Browse drugs

…ime since severe asthma diagnosis was 6 (±6) years, with a mean omalizumab treatment persistence of 5 (±4) years and a Dm of 477 (±115) mg…

…umab (28.6%) and dupilumab (14.3%), there were no patients with omalizumab.Conclusion and Relevance 70.8% of corticosteroid dependent pati…

…sturbances and activity limitations. Biologic therapies such as omalizumab and dupilumab are established options for antihistamine-refract…

…0) • Mepolizumab 0 (0) • Benralizumab 1 (9) • Dupilumab 1 (9) • Tezepelumab 6 (55) • None 2 (18) Prior biological therapy use n% 0 4 (36) 1…

…the only without polysorbate). Consequently, desensitisation to tezepelumab was proposed.Results The content of the commercial pen (CP) (21…

… 41.9% allergy and atopic dermatitis. Biologics prescribed were omalizumab (61.4%), dupilumab (22.7%), mepolizumab (11.4%), and tezepeluma…

… patients were included (mean age 58.5±13.2 years; 62.7% male). Tezepelumab was used as first-line in 25/52 (48.1%), second-line in 15/52 (…

…enralizumab, dupilumab, mepolizumab, omalizumab, reslizumab and tezepelumab, were estimated using Medicine Carbon Footprint Classifier, a s…

…umab n=442, dupilumab n=69, mepolizumab n=146, omalizumab n=51, tezepelumab n=69, not recorded n=29. 49.3% of patients were taking maintena…

… benralizumab, 27.3% to 36.4% for dupilumab, 24.2% to 40.9% for mepolizumab, and 11.1% to 33.3% for omalizumab from Year 1 to Year 3. Basel…

… 0/44 (0.0%) 0/44 (0.0%) NA 50/230 (21.7%) 36/141 (25.5%) 0.475 Omalizumab NA NA NA 0/44 (0.0%) 0/44 (0.0%) NA 36/236 (15.3%) 16/141 (11.3…